Details of the Drug Combination

General Information of Drug Combination (ID: DCSC6QI)

• Drug Combination Name: ACER-001 + Valganciclovir
• Indication: Gastric Cancer; Status: Phase 1 [1]
• Component Drugs:
  ACER-001 (DM9HJFJ): N.A.
  Valganciclovir (DMS2IUH): Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Indication(s) of ACER-001

Disease Entry	ICD 11	Status	REF
Maple-syrup-urine disease	5C50.D0	Investigative	[2]

Indication(s) of Valganciclovir

Disease Entry	ICD 11	Status	REF
Virus infection	1A24-1D9Z	Approved	[3]

Valganciclovir Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Herpes simplex virus DNA polymerase UL30 (HSV UL30)	TTIU7X1	DPOL_HHV11	Inhibitor	[4]

Valganciclovir Interacts with 2 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
Peptide transporter 1 (SLC15A1)	DT9G7XN	S15A1_HUMAN	Substrate	[5]
Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)	DTW7AE3	AAAT_HUMAN	Substrate	[6]

References

• [1] ClinicalTrials.gov (NCT00387530) Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4716).
• [4] Drug targets in cytomegalovirus infection. Infect Disord Drug Targets. 2009 Apr;9(2):201-22.
• [5] Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci. 2000 Jun;89(6):781-9.
• [6] Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0,+). Pharm Res. 2004 Jul;21(7):1303-10.